The Seprion™ range of products detect aggregated proteins associated with Parkinson’s, Alzheimer’s, Huntington’s diseases, and the Transmissible Spongiform Encephalopathies such as BSE, scrapie, vCJD and CWD. We have commercialised our Seprion™ BSE product, with a US partner, and this dominates the worldwide market for prion disease testing.
For diagnosis, detection and research studies it is very difficult to differentiate the abnormal aggregated form of the proteins from the normal unaggregated form. To address this problem, we have developed polymeric ligands (our Seprion™ range) which only bind to the abnormal or altered aggregated form of the protein. The Seprion™ ligands have been proven to bind abnormal prion, β-amyloid, α-synuclein, tau, huntingtin and aggregated p53 in cancer cells. They can also be used to monitor the aggregation state of manufactured therapeutic proteins such as antibodies.